A pathway of costimulation that prevents anergy in CD28- T cells: B7- independent costimulation of CD1-restricted T cells by unknown
A Pathway of Costimulation That Prevents Anergy in
CD28- T Cells: B7-independent Costimulation of
CD1-restricted T Cells
By S. M. Behar, S. A. Porcelli, E. M. Beckman, and M. B. Brenner
From the Division ofLymphocyte Biology, Department ofRheumatology and Immunology, Brigham
and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Summary
A class of molecules that is expressed on antigen presenting cells, exemplified by CD80 (137),
has been found to provide a necessary costimulatory signal for T cell activation and prolifera-
tion. CD28 and CTLA4 are the 137 counterreceptors and are expressed on the majority of hu-
man CD4+ T cells and many CD8+ T cells. The signal these molecules mediate is distin-
guished from other costimulatory signals by the finding that T cell recognition of antigen
results in a prolonged state of T cell unresponsiveness or anergy, unless these costimulatory
molecules are engaged. However, nearly half of the CD8+ and CD4-CD8- T cells lack
CD28, and the costimulatory signals required for the activation ofsuch cells are unknown. To
understand the pathways of activation used by CD28- T cells, we have examined the costimu-
latory requirements of antigen-specific CD4-CD8- TCR+-ot/(3 circulating T cells that lack
the expression of CD28. We have characterized two T cell lines, DN1 and DN6, that recog-
nize a mycobacterial antigen, and are restricted not by major histocompatibility complex class I
or 11, but by CD1b or CD1c, two members of a family of major histocompatibility complex-
related molecules that have been recently implicated in a distinct pathway for antigen presenta-
tion. Comparison of antigen-specific cytolytic responses of the DN1 and DN6 T cell lines
against antigen-pulsed CD1+ monocytes or CD1+ B lymphoblastoid cell lines (B-LCL) dem-
onstrated that these T cells recognized antigen presented by both types of cells. However, T
cell proliferation occurred only when antigen was presented by CD1+ monocytes, indicating
that the CD1+ monocytes expressed a costimulatory molecule that the B-LCL transfectants
lacked. This hypothesis was confirmed by demonstrating that the T cells became anergic when
incubated with the CD 1+-transfected B-LCL in the presence ofantigen, but not in the absence
of antigen. The required costimulatory signal occurred by a CD28-independent mechanism
since both the CD1+ monocytes and CD1+ B-LCL transfectants expressed 137-1 and 137-2,
and DN1 and DN6 lacked surface expression of CD28 . We propose that these data define a
previously unrecognized pathway of costimulation for T cells distinct from that involving
CD28 and its counterreceptors. We suggest that this 137-independent pathway plays a crucial
role in the activation and maintenance of tolerance of at least a subset of CD28- T cells.
ost human T cells express TCRs that recognize pep-
tide antigens bound to class I or class II MHC mole-
cules. However, formation of the TCR-peptide-MHC
molecule ternary complex does not generate a signal suffi-
cient to cause T cell activation and proliferation; additional
costimulatory signals are also required (1) . One such critical
costimulatory signal is transmitted through the T cell sur-
face molecule CD28 when it binds its ligands CD80 (137-1)
or CD86 (1370/137-2) (2-7), which are expressed on APC
such as activated B cells, monocytes, and dendritic cells (8,
9). If cross-linking of the TCR by peptide-MHC com-
plexes or by anti-CD3 antibody occurs in the absence of
this costimulatory signal, then a state of prolonged unre-
sponsiveness of the T cell to antigen is induced (10, 11).
The induction of this unresponsive state, referred to as T
cell anergy, may be an important mechanism of peripheral
tolerance that prevents the activation of circulating autore-
active T cells that have escaped thymic deletion (12-14).
Although the majority of circulating T cells expresses the
TCR-ot/(3 and either CD4 or CD8, a subset of mature pe-
ripheral blood T cells expresses neither the CD4 nor the
CD8 markers and is termed double negative (DN) .t In
general, the circulating pool of CD4-8- T cells contains
most ofthe TCR--y/8+ cells, and also a consistently detect-
'Abbreviations used in this paper: B-LCL, B lymphoblastoid cell line; DN,
double negative.
2007
￿
J. Exp. Med. © The Rockefeller University Press " 0022-1007/95/12/2007/12 $2.00
Volume 182 December 1995 2007-2018able subpopulation of TCR-cx/R+ cells (15). CD4-8-
TCR-o /(3+ T cells are found in bone marrow, lymph
nodes, thymus, and epidermis (16), and expansions up to
20% of CD3+ cells are found in the peripheral blood of
some normal individuals (15) and in patients with autoim-
mune diseases (17-21). The absence of the CD4 and CD8
coreceptors from DN T cells suggests that they may not in-
teract with MHC class I and class II molecules during anti-
gen presentation, and several previous studies have impli-
cated the non-MHC-encoded CD1 family of cell surface
proteins as important antigen presenting molecules for
these T cells (22-28).
The human CD1 locus consists offive genes (CD1A, -B,
-C, -D, and -E) that encode type I transmembrane glyco-
proteins that have limitedbut detectable homology to MHC
proteins, and they are expressed on many professional APC
in association with (32-microglobulin (26, 28-36). High lev-
els of CD1 can be induced in vitro by culturing monocytes
in the presence ofGM-CSF and IL-4 (23, 37). Such mono-
cytes (hereafter referred to as CD1+ monocytes) are able to
present microbial antigens to CD1-restricted T cells and in-
duce their proliferation (23, 24). Previously, we have shown
that some CD4-8- TCR-ot/R + T cells recognize antigens
restricted by the non-MHC-encoded CD 1b molecule (23,
24). Recently, the antigen recognized by the prototype
CDlb-restricted T cell line DN1 was identified as mycolic
acid, a complex and structurally variable fatty acid that is
part of the mycobacterial cell wall (25) .
Several studies have documented the absence of CD28
expression on a substantial fraction of circulating CD4-8-
and CD4-8+ T cells (38, 39), raising questions about the
costimulatory requirements of these cells. This study sought
to determine whether CD28- T cells lack a requirement
for costimulation in contrast to their CD28+ counterparts,
or alternatively use a distinct costimulatory pathway. Here,
using the CD1-restricted DN1 and DN6 T cell lines, we
show that CD28- TCR-ot/R+ T cells required costimula-
tion that was independent of the 137-CD28 axis. These
data revealed the existence ofa distinct pathway for costim-
ulation of CD28- T cells.
Materials and Methods
Antibodies. The following antibodies were used: P3 (IgGj ,
nonbinding control [40]); W6/32 (anti-HLA-A, -B, -C [41];
murine IgGI; American Type Culture Collection, Rockville,
MD); L243 (anti-HLA-DR, murine IgG2,; American Type Cul-
ture Collection) ; IT2 (anti-1370/137-2 [4], IgGI ; gift of Ko Oku-
mura, Juntendo, University School of Medicine, Tokyo, Japan);
BB-1 (anti-137 [42], murine IgM; gift ofEd Clark, University of
Washington, Seattle, WA); 9.3 and 11D4 (anti-CD28, murine
IgG2, and anti-CTLA4 [43], murine IgGI , respectively; gift of
Peter Linsley, Bristol-Myers Squibb, Seattle, WA).
Antigens.
￿
200 mg of desiccated Mycobacteria tuberculosis bacilli
(strain H37Ra; Difco Laboratories Inc., Detroit, MI) was soni-
cated in 5 ml PBS, followed by centrifugation at 100,000g to re-
move insoluble material. Protein content was assayed using the
Bradford method (Bio-Rad Laboratories, Melville, NY). A pro-
tein concentration of 10 lLg/ml corresponds to a 1:30-1:60 dilu-
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tion of the sonicate. Recombinant C fragment of tetanus toxin
(Boehringer Mannheim Corp., Indianapolis, IN) was reconsti-
tuted in PBS.
Cell Culture.
￿
DN1 (23) and DN6 (Beckman, E. M., A. Me-
lian, S. M. Behar, P. A. Seiling, D. Chattedee, R. Matsumoto,
J. P. Rosat, R. L. Modlin, and S. A. Porcelli, manuscript in prep-
aration) are CD4-8- TCR-a/R+ T cell lines that recognize M.
tuberculosis antigens presented by CD1b and CDlc, respectively.
The DN1 and DN6 T cell lines were derived independently from
different human donor's PBL depleted of CD4+ and CD8+ T
cells. The DN T cells were repeatedly stimulated with M. tubercu-
losis sonicate, using allogeneic CD1+ monocytes as APC that ex-
press high levels of CDla, CDlb, and CDlc. SP-173 and SP-1714
(gifts of Dr. Hergen Spits, Netherlands Cancer Institute, Amster-
dam, The Netherlands) are human CD4+ T cell clones that rec-
ognize the C fragment of tetanus toxoid restricted by HLA-DR
(44) . All T cells were grown in RPMI 1640 supplemented with
10 mM Hepes, 2 MM L-glutamine, 10 mM nonessential amino
acids, 10 mM essential amino acids, 0.055 mM 2-ME (all from Life
Technologies Inc., Gaithersburg, MD), 10% heat-inactivated
FCS (Hyclone Laboratories Inc., Logan, UT), and 1.5 nM rIL-2
(gift of Ajinomoto Company, Kawasaki,Japan) .
The B lymphoblastoid cell line (B-LCL) ClR (45) was trans-
fected with the expression vector pSRot-NEO (46) containing ei-
ther the CDla, CDlb, or CDlc cDNA (47), or with the vector
alone. Stably transfected cells were first selected for G418 resis-
tance and then for high surface expression ofthe relevant proteins
usingimmunomagnetic bead selection. Clones were subsequently
established by limiting dilution. ClR was grown in RPMI 1640
medium supplemented with 10% heat-inactivated FCS, 10 mM
Hepes, 2 MM L-glutamine, 10 mM nonessential amino acids, 10
mM essential amino acids, and0.055 mM 2-ME.
Human blood monocytes were isolated from leukocyte con-
centrates obtained from volunteerplatelet pheresis donors and in-
cluded CMV-seropositive and -seronegative individuals. Human
PBMC were prepared by Ficoll-Paque (Pharmacia, Uppsala,
Sweden) density centrifugation, and monocytes were enriched by
isolating plastic adherent cells (23). CD1 expression was induced
on the monocytes by culturing the cells with 200 U/ml of GM-
CSF (gift of Genetics Institute, Cambridge, MA) and 100 U/ml
of IL-4 (gift of Schering Corp., Bloomfreld, NJ) for 60 h as de-
scribed (23) .
FACS©.
￿
2 X 105 T cells or monocytes were stained with 50
Rl of ascites (diluted 1:400) or purified antibody (5 N.g/ml) in
FRCS' buffer (5% bovine calfserum/0.01% azide) for 1 h at 4°C.
The cells were washed, and 20 ltl of FITC-labeled F(ab')2 goat
anti-mouse Ig (Tago, Inc., Burlingame, CA) (diluted 1:30) was
added for 1 h at 4°C. Afterwashingextensively with FACS' buffer,
the cells were counterstained with propidium iodide and analyzed
usinga FACSort® (Becton Dickinson & Co., Raritan, NJ).
Cytotoxicity.
￿
ClR lymphoblastoid cell lines stably transfected
with the CDla, CDlb, or CD1c genes, or mock transfected
(vector alone) were used as targets in astandard "Cr release assay.
Targets were pulsed for 16 h with the M. tuberculosis antigen
preparation (10 la,g protein/ml) and then labeled with 200 p,Ci of
"Cr for 2 h. 2,000 target cells were incubated with effector T
cells for 4 h in triplicate, and the E/T ratio varied as indicated in
Fig. 1, A and B. Cr release was assessed by counting 25 RI ofthe
supernatant in a liquid scintillation counter. Specific lysis was cal-
culated as (sample cpm - spontaneous cpm)/(maximum cpm -
spontaneous cpm) X 100.
Proliferation.
￿
T cellswere cultured in triplicate at a concentra-
tion of 5 X 104 cells per well in the presence of 5 X 104 alloge-neic irradiated (5,000 mad) CD1' monocytes or 5 X 104 mito-
mycin C (Sigma Chemical Co., St. Louis, MO)-treated CD1+
B-LCL in a flat-bottomed 96-well plate in a total volume of 200
li,l per well. Antigen, antibodies, or cytokines were added to the
final concentrations indicated in the figures. The cultures were
incubated fora total of72 (for DN6) or 120 (for DN1) h at 37°C
in 5% COz and pulsed with 1 RCi of [3H]thymidine (6.7 Ci
mmol-I; New England Nuclear, Boston, MA) per well for the
last 6 h of culture, and 3H incorporation was measured by liquid
scintillation counting to assess T cell proliferation. Cultures were
harvestedonto fiberglass filtermats (Wallac, Gaithersburg, MD) us-
ing an automated harvester (Tomtec, Orange, CT) and counted
using a liquid scintillation counter (model 1205 Betaplate; Wal-
lac) . In general, thestandard deviation of the triplicates was 5-10%
ofthe mean.
Induction ofAnergy.
￿
The B-LCL CIR, stably transfected with
CDlb or CDlc (ClR.CDlb or ClR.CDlc), was cultured with
or without the appropriate antigen for 16 h and then extensively
washed. The APC were treated with mitomycin C and then cul-
turedin 24-well plates (Linbro, Horsham, PA) with restingDN1
or DN6 T cellsat a ratio of 10 APC/1 T cell for 48 h. Viable cells
were isolated using density centrifugation and were then restimu-
lated with CD1' monocytes and M. tuberculosis antigen in a pro-
liferation assay as describedabove.
IL-2 Assay.
￿
The amount of IL-2 produced by DN1 and
DN6 T cells was determined using a bioassay in which culture
supernatants were tested for their ability to stimulate the growth
of the IL-2-dependent CTLL-20 T cell line (48) . DN1 or DN6
culture supernatants were sampled 24 h after antigen stimulation
andassayed at a 1:4 dilution, using 5,000 CTLL-20 cells persam-
ple. The proliferation of the CTLL-20 T cells was assessed by
measuring [3H]thymidine incorporation during the last 6 h of a
24-h culture.
Transwell Assays.
￿
The dependency ofthe costimulatory signal
on cell-cell contact was determined using a 24-well format trans-
well culture system that used a polycarbonate membrane with a
0.4-[Lm pore size (Costar Corp., Cambridge, MA). 3 X 105 T cells
were cultured together with 3 X 105 ClR.CDlb or CIR.CD1c
cells and M. tuberculosis antigen in each lower (cluster) well. The
upperwell (transwell) contained either medium or 5 X 104 CD1+
monocytes and antigen. Proliferation was assessed as described
above.
Production ofHybridomas.
￿
6-wk-old fenmale BALB/c mice (The
Jackson Laboratory, Bar Harbor, ME) were immunized intraperi-
toneally with 107 CD1' monocytes in PBS and boosted 4 wk
later in the same manner. Mice used for the production ofhybri-
domas were given a third intraperitoneal immunization with 107
CD1' monocytes, and, 3 d later, splenocytes were fused to the
myeloma fusion partner NSO (49) using polyethylene glycol (50).
Supernatants from wellscontaining hybridomas were screened for
their ability to inhibit the proliferation of the DN1 T cell line.
Hybridomas from positive wells were cloned twice by limiting
dilution. The IgG1 mAb BCDlb3.1 inhibitedDN1 T cell prolif-
eration by >90% and was specific for CD1b as determined by
flow cytometry using the CDla, -b, and -c transfectants of the
B-LCL C1R (Behar, S. M., unpublished observations). BCDIb3.1
was purified from ascites using protein A-Sepharose (Pharmacia).
Results
The CD28- DN1 and DN6 TCells Required a Costimula-
tory Signal That Was Provided by CD 1+ Monocytes, but Not by
CD1f B-LCL.
￿
DN1 and DN6 are independently derived
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mycobacteria-specific, C131-restricted human T cell lines
that are CD4-8- TCR-a/[3+ (23, 25, and Beckman, E. M.,
A. Melian, S. M. Behar, P. A. Seiling, D. Chatterjee, R.
Matsumoto, J. P. Rosat, R. L. Modlin, and S. A. Porcelli,
manuscript in preparation) . Previously, we established cell
lines that could be used as APC for CD1-restricted T cells by
transfecting the ClR B-LCL with the CD1a (CIR.CDla),
CDlb (CIR.CDlb), or CDlc (ClR.CDlc) cDNA ex-
pression constructs (23). Mycobacterial extract-pulsed
ClR.CDlb, butnot CIR.CDla, ClR.CDlc, or ClR.mock
targets, were specifically lysed by the DN1 T cell line (Fig.
1, A and B). In contrast, the DN6 T cell line specifically
recognized only antigen-pulsed CIR.CDlc targets. In the
absence of antigen, none of the CD1-transfected C1R cell
lines were lysed by DN1 (23). In some experiments, the
DN6 T cell line did lyse the ClR.CDlc targets. The spe-
cific lysis was 10-fold less than the antigen-specific lysis and
was due to the presence ofsome CD 1c-autoreactive T cells
in the DN6 T cell line (Beckman, E. M., A. Melian, S. M.
Behar, P. A. Seiling, D. Chatterjee, R. Matsumoto, J. P.
Rosat, R. L. Modlin, and S. A. Porcelli, manuscript in
preparation). Recognitionwasblocked with anti-CDlb an-
tibodies (for DN1) or anti-CDlc antibodies (for DN6), but
not with anti-MHC class I or anti-MHC class II antibodies
(23, and Porcelli, S. A., unpublished results). These results
demonstrated that C1R B lymphoblastoid cells could pro-
cess and present the relevant antigenic determinants, pro-
vided that the appropriate form of CD1 was expressed.
However, these same antigen-pulsed ClR CD1+ transfec-
rants failed to induce DN1 or DN6 proliferation under con-
ditions in which CD1' monocytes inducedmarked [3H]TdR
incorporation (Fig. 1, C and D). Treatment of the CD1b+
B-LCL with GM-CSF and IL-4 did not modify the ability
of these APC to stimulate the proliferation of the DN1 T
cell line. Similarly, DN1 and DN6 only produced IL-2
when stimulated by antigen-pulsed CD1' monocytes,
whereas no IL-2 was detected after stimulation by the ap-
propriate CD1' B-LCL transfectant and antigen (Fig. 1, E
and F) . These findings suggested that the CD1' monocytes,
but not CD1' B-LCL, provided a costimulatory signal that
was required by DN1 and DN6 for proliferation and IL-2
production, but not for cytotoxic activity.
The Costimulatory Signal Required by the DN TCR-a//3+
TCell Lines Was Independent of the CD28-B7Axis. Nota-
bly, neither the DN1 nor the DN6 T cell lines stained with
mAb 9.3 in flow cytometric analysis, indicating that these
T cells lack expression of the T cell-costimulatory mole-
cule CD28, even 72 h after activation with antigen and
CD1+ monocytes (Fig. 2 and data not shown). Activation
with PMA and ionomycin, which has been reported to in-
crease the expression of CD28 by resting T cells, did not
induce the expression of CD28 on DN1 T cells, and little if
any expression was seen for the DN6 T cell line. The DN1
andDN6 T cell lines may be representative ofotherT cells
that lack CD28 expression, which include up to half of the
circulating CD8+ TCR-ct/[3+ and TCR-y/8+ T cells in
humans (38, 39, 51). In contrast, SP-F3 and SP-1`14, two
CD4+ TCR-a/[3 + human T cell clones specific for the C0
_T
U
w
N
a
W
120
M
0
80
E
C
0
v' 40
o.
E
1 5 20 50 1 5 20 50
E:T ratio
36
24
12
F
Lr 0
0
￿
0016
￿
04
￿
1
￿
0 0
11
.08
M. Tb. (pg/ml)
0
x
U
C
_O
w
O
n
30-
fragment of tetanus toxoid, constitutively expressed CD28
(Fig . 2) .
Another T cell surface protein, CTLA4, has been identi-
fied as a counterreceptor for the B7 family of costimulatory
ligands, and it was thus of interest to examine the expres-
sion ofthis protein by DN1 and DN6 T cells (4, 6, 52, 53) .
CTLA4 is expressed only by CD28+ T cells in peripheral
blood, and in nearly all cases so far reported, this is also true
for T cells grown in vitro (54, 55) . No cell surface expres-
sion of CTLA4 was detected on resting cultures of either
the DN1 or DN6 T cell lines (data not shown) . In contrast
to the resting phenotype of these cells, activation by PMA
and ionomycin induced some surface expression ofCTLA4
(Fig . 2) . However, whereas CD28 clearly functions as a T
cell-costimulatory molecule, recent data suggest that
CTLA4 is a negative regulator of the T cell immune re-
sponse and may induce apoptosis ofT cells (56, 57) . Thus,
it was unlikely that CTLA4 would be able to substitute for
CD28 in activation ofDN1 and DN6, and the absence of
CD28 suggested that another costimulatory pathway was
operating for these T cells .
The pivotal role of the well-studied CD28-137 pathway
in the costimulation ofCD4' and CD8+ T cells and in the
prevention ofT cell anergy led us to assess if differences in
stimulatory potential of the CD1 + monocytes compared
with the C1R B-LCL was a consequence of a discrepancy
in the expression ofB7 on these two APC . The surface ex-
pression ofCD80 (137-1) and CD86 (1370/137-2) on ClR
cells and CD1' monocytes was determined by flow cy-
tometry . The CD1' monocytes constitutively expressed
both CD80 and CD86 (Fig . 3), similar to what has been re-
ported for unstimulated monocytes and dendritic cells .
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Figure 1 . Differential response of CD1-restricted antigen-specific T cells to
monocyte and B-LCLAPC . DN1 (A) and DN6 (B) T cells lysed CDlb' or CDlc'
antigen-pulsed target cells, respectively. ClR cells stably transfected with the CDla,
CD1b, and CDlc cDNAs, or mock transfected (vector alone), were pulsed for 16 h
with the mycobacterial antigen preparation (10 ltg/ml) and used as targets in a stan-
dard 4-h "Cr cytotoxicity assay . DN1 (C) and DN6 (D) proliferated in response to
antigen presented by CD1' monocytes but not CDl' B-LCL . DNl orDN6 T cells
were cultured with medium alone (indicated by 0 Ltg/ml) or withM. tuberculosis son-
icate at the indicated concentrations and CD1' monocytes or CIR transfectants for
3 d (DN6) or 5 d (DN1) . DN1 (E) and DN6 (F) produced IL-2 after recognition of
antigen presented by CD1' monocytes but not by CD1' B-LCL. DNl was stimu-
lated with media alone (indicated by 0 p.g/ml) or mycobacterial antigen at the indi-
cated concentrations in the presence of either ClR.CDlb, CIR.CDlc, or CDl'
monocytes . After 24 h, supernatants were sampled, diluted 1 :4, and tested for their
ability to induce the proliferation of the CTLL-20 IL-2-dependent T cell line . m,
ClR.CDla ; O, CIR.CDlb ; O, ClR.CDlc ; O, ClR.mock; M, CD1' monocytes .
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Similarly, CD80 and CD86 were detected on ClP,.CD1b
cells (Fig . 3) . In fact, the cell surface expression of CD80
and CD86 on the ClR cell line exceeded the levels ob-
served on the CD1+ monocytes . Since CD80 and CD86
were expressed on both ClR cell lines as well as the CD1+
monocytes, differences in the expression of the B7 family
of costimulatory molecules failed to explain the divergent
capacity of these APC to provide costimulation to DN1
and DN6 . These findings cannot be ascribed to some func-
tional deficit in the 137-1 or 137-2 molecules expressed by
ClR, since these cells efficiently supported the prolifera-
tion ofCD28+ T cells (see below) .
It has been observed that B7 is functionally active even
when expressed at low levels on APC, and we considered
whether this could be true for CD28 as well . To be certain
that DN1 proliferation was independent of the CD28-137
pathway, we studied the effect ofCTLA4-Ig on the prolif-
eration ofDN1 . CTLA4-Ig binds avidly to CD80 and CD86
and blocks their interaction with CD28, thereby prevent-
ing CD28-mediated costimulation. CTLA4-Ig did not block
the proliferation ofDN1 (Fig . 4 A), even at concentrations
that were sufficient to inhibit anMLR by 80-90% (Fig . 4 B) .
This indicated the existence of one or more non-CTLA4-
binding costimulatory molecules required for the optimum
proliferation ofT cell line DN1 .
The Costimulatory Signal Used by the CD28- DN TCR-
a/,(3+ T Cells Required Cell-Cell Contact . We next sought to
determine whether the costimulatory signal provided by
the monocytes was mediated by a soluble molecule, or al-
ternatively, required cell-cell contact . Previous studies have
shown that antigen-pulsed, glutaraldehyde-fixed CD1+
monocytes are able to stimulate the proliferation of theMHC
class I
CD28
(resting)
CD28
(activated)
CTLA4
(activated)
DN1
￿
DN6 SP-F3 SP-F14
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DN1 T cell line (23), suggesting that the costimulatory sig-
nal is probably a membrane-bound molecule and unlikely
to be a secreted monokine. To strengthen this conclusion,
transwell experiments were carried out using both DN1
and DN6. In these experiments, the T cell lines and anti-
gen-pulsed ClP, CD1b or CD1c transfectants were sepa-
rated from irradiated unfixed CD1+ monocytes by cellulose
acetate membranes (0.4-~Lrn pore size). T cell proliferation
occurred only when there was cell-cell contact between
the CD1+ monocytes and the DN1 or DN6 T cell line
(Table 1), indicating that the costimulatory signal provided
by the CD1+ monocytes was not a soluble factor. This
conclusion was supported by the finding that antigen unex-
posed CD1 + monocytes cocultured with antigen-pulsed
ClP,.CDlb did not stimulate DN1 T cell proliferation
(data not shown) .
Figure 2.
￿
The expression of CD28 on the DN1 and DN6 T cell lines. Surface expression ofCD28 was determined by flow cytometry on in vitro-cul-
tured T cell lines using "resting cultures" (i.e., >2 wk since last restimulation), or cells that had been activated using PMA (10 ng/ml) and ionomycin (1
p,g/ml) for 24 h. The following T cells were used: DN1 (CD4-CD8- TCR-a/(3+; CDlb restricted; specific for M. tuberculosis); DN6 (CD4-CD8-
TCR-a/13+; CDlc restricted; specific for M. tuberculosis); SP-F3 (CD4+ TCR-a/(3+ ; HLA-DR restricted; specific for tetanus toxoid); SP-1`14 (CD4+
TCR-a/(3+; HLA-DR restricted; specific for tetanus toxoid). The cells were stained using P3 (isotype-matched negative control), W6/32 (anti-MHC
class 1), or 9.3 (anti-CD28) . Rows 1 and 2 are resting T cells. Rows 3 and 4 are T cells activated with PMA and ionomycin. The fluorescent channel
number is plotted along the x-axis, and the y-axis represents the relative cell number.
CD28- T Cells Became Anergic upon Recognizing Antigen
in the Absence ofa Costimulatory Signal. Ptevious studies have
shown that if a TCR-mediated signal is delivered to the T
cell in the absence of a costimulatory signal, anergy rather
than proliferation occurs. This paradigm predicts that, if an
essential costimulatory molecule were absent from the B-LCL,
DN1 and DN6 T cells should become anergic upon recog-
nition of antigen presented by the ClR.CDlb and
C1R.CD1c cell lines since their TCRs are being engaged
in the absence of costimulation. On the other hand, anergy
should not occur if the T cells and the C1R transfectants
are cultured together in the absence ofantigen, as the TCR
would not be stimulated.
To test this hypothesis, DN1 T cells were cultured for
48 h with ClR.CDlb APC that had been pulsed with
M. tuberculosis extract. DN1 treated in this way did not pro-CD1+ B-LCL (C1 R.CD1b)
liferate when restimulated by CD1+ monocytes and M. tu-
berculosis antigen (Fig. 5 A), a condition that supported this
proliferation without such pretreatment (Fig. 1 Q. This
observed hyporesponsiveness ofthe DNl T cells was a con-
sequence of T cell anergy and not due to a loss of viability
of the T cells, because DN1 T cells recultured in the pres-
ence of IL-2 proliferated well. In contrast, ifDN1 were first
cocultured with CIR.CDlb APC in the absence of M. tu-
berculosis antigen, anergy did not occur, as indicated by a nor-
mal proliferative response to rechallenge with CD1+ mono-
cytes and antigen. DN6 also became anergic after coculture
with antigen-pulsed ClR.CDlc (Fig. 5 B). Like DN1, the
induction of anergy in DN6 was antigen specific and re-
stricted by the same form of CD1 that restricted the T cell
proliferative and CTL responses (i.e., CDlc in this case).
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The expression of CD80 (137-
1) and CD86 (B70/B7-2) on CD1 + mono-
cytes and ClR.CDlb. The binding of
mAbs BB-1 (CD80) and IT2 (CD86) were
compared on the CD1+ monocytes and
C1R.CD16. A negative control and HLA-
DR expression are shown as controls. The
fluorescent channel number is plotted along
the x-axis, and the y-axis represents the rel-
103 101
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IT2 (B7-2)
A high APC/T cell ratio during the preincubation with
the ClR transfectants was required for the induction of an-
ergy. Anergy resulted only when the appropriate form of
CD1 was expressed by CIR, since the ClR mock trans-
fectant failed to induce anergy in either T cell line, regard-
less ofwhether it was pulsed with antigen or not. As a con-
trol for antigen specificity, tetanus toxoid (recombinant C
fragment)-pulsed CIR cells did not induce anergy . Fur-
thermore, the induction of anergy was dependent on the
M. tuberculosis antigen concentration. For DN1, pulsing
ClR.CDlb with 1 jig/ml was as effective as 25 jig/ml;
however, DN6 required 10-25 jig/nil for a maximal ef-
fect. This is consistent with DNI being more sensitive by
at least an order of magnitude than DN6 to stimulation
with M. tuberculosis and CD 1 + monocytes (Fig. 1, C and D).
Figure 4. The antigen-induced proliferation of
DNI was not inhibited by CTLA4-1g. (A) DNI
was stimulated using CD1+ monocytes and differ-
ent concentrations of M. tuberculosis sonicate in the
presence of CTLA4-Ig (10 ltg/ml), human IgGI
(10 Il.g/ml), or no antibody. (B) At 10 Ltg/nil,
CTLA4-Ig blocked T cell proliferation induced by
a mixed lymphocyte reaction by 80%. ", Human
IgGl; ", CTLA4-[g; m, no antibody.CD1+ monocytes or CD1 + B-LCL were cultured with mycobacterial
antigen and the DNl or DN6 T cell line in the lower well (cluster well)
of a transwell plate. The upper well (transwell) contained either me-
dium alone or CD1+ monocytes and mycobacterial antigen and was
separated from the lower well by a semipermeable cellulose acetate
membrane (0.4 ll.m pore size). The cells in the lower well were pulsed
with [3H]TdR for 6 h after 3 d (for DN6) or 5 d (for DN1), and the
thymidine incorporation was measured. M~, monocytes; MTb, M. tu-
berculosis antigen.
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Figure 5.
￿
Induction ofanergy in CD28- T cells. (A) DN1 T cells became
anergic when stimulated by antigen-pulsed C1R.CD16 cells. DN1 was co-
cultured with either mycobacterial antigen-pulsed (1 pl,g/ml) ClR.CDlb
cells (") or with unpulsed ClR.CDlb cells (0) for 48 h. The T cells were
then isolated and restimulated with CD1+ monocytes in the absence (me-
dium alone) or presence of mycobacterial antigen at the indicated con-
centrations, or with IL-2 (2 nM). The assay was harvested on day 5 after a
6-h pulse with 1 1LCi/well of [3H]TdR. (B) DN6 became anergic when
stimulated by antigen-pulsed C1R.CDlc cells. DN6 was cocultured with
either mycobacterial antigen-pulsed (10 Fag/ml) ClR.CDlc cells (0) or
with unpulsed CIR.CDlc (0) cells for 48 h. The T cells were then iso-
lated and restimulated as described above for DN1 . The assay was har-
vested on day 3 after a 6-h pulse with 1 1LCi/well of [3H]TdR.
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￿
Human antigen-specific CD28+ T cell clones proliferated to
antigen presented by either the ClR B-LCL or the CD1+ monocytes.
SP-1`3 or SP-1`14 T cells were cultured together with CD1+ monocytes
or CD1+ CIR cell lines in the presence (solid bars) or absence (open bars)
of 10 N,g/ml ofsoluble C fragment ofrecombinant tetanus toxin. The as-
say was harvested on day 3 after a 6-h pulse with 1 1t.Ci/well of[3H]TdR.
Although the CD1 transfectants of the ClR cell line
were unable to stimulate the proliferation ofDN1 or DN6,
B-LCLs are generally potent APC for in vitro stimulation
of MHC-restricted T cell responses to soluble antigens
since they are able to process antigen and express 137 and a
full array of cell adhesion molecules. In fact, the ClR cell
line was capable of stimulating the proliferation of human
CD4+ T cells. Two tetanus toxoid-specific HLA-DR-
restricted CD4+ T cell clones, SP-F3 and SP-1`14, prolifer-
ated when the C fragment of tetanus toxoid was presented
by the CIR transfectants (Fig. 6) . In direct contrast to the
results obtained with DN1 and DN6, when ClR.CDlb
cells were pulsed with 10 ~Lg/ml of the tetanus toxoid C
fragment and then incubated with SP-F3, anergy was not
induced in SP-F3 (Fig. 7) . These experiments clearly dem-
onstrated the existence of different requirements for the
costimulation and anergy induction for these representative
CD4+CD28+ T cell clones (SP-F3, SP-1`14), in contrast to
the CD28- DN T cell lines (DN1, DN6) . Thus, the in-
duction of anergy in DN1 and DN6 after the recognition
ofantigen presented by the B-LCL CD1 transfectants strongly
indicated that the DN T cells have a unique costimulatory
requirement.
Figure 7.
￿
SP-1`3 T cells did not become anergic when stimulated by
antigen-pulsed ClR.CD16. SP-F3 was cocultured with ClR.CDlb cells
pulsed with the recombinant C fragment oftetanus toxin (10 lag/ml) (*)
or with unpulsed ClR.CDlc (0) cells for 48 h. The T cells were then
used in a proliferation assay using CD1+ monocytes as the stimulators in
the absence (medium alone) or presence of tetanus toxin C fragment at
the indicated concentrations, or with IL-2 (2 nM) . The assay was har-
vested on day 3 after a 6-h pulse with 1 ltCi/well of[3H]TdR.
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Table 1 . Requirementfor Cell-Cell Contact in
CD28- T Cells
Costimulation of
Upper well Lower well cpm (lower well)
- CD1+ M-fl, + MTb + DNl 39,603 ± 1,930
- ClR.CDlb + MTb + DN1 205 - 1- 10
CD1+
M-fl, + MTb ClR.CDlb + MTb + DN1 194 - *- 76
- CDl+ M~b + MTb + DN6 87,624 ± 10,890
- ClR.CDlc + MTb + DN6 28 ± 6
CDl+
Mo~ + MTb ClR.CDlc + MTb + DN6 31 -} 9Figure 8 .
￿
Anti-CDlb antibody prevented the induction of anergy. An-
ergy was induced as described in the legend of Fig. 3 . 10 Wg/ml ofmAb
BCD1b3 .1 (anti-CDlb) was added during the preincubation where indi-
cated. Restimulation conditions : MTb 5 ng/ml (solid bars), no antigen
(open bars) ; 2 nM IL-2 (hatched bars) .
Anti-CDl b mAbs Blocked the Induction of Anergy .
￿
The
two-signal model ofT cell activation predicts that if signal
one (TCR mediated) is blocked, then neither T cell prolif-
eration nor T cell anergy will occur. This hypothesis was
tested using the anti-CD 1b mAb BCD1b3.1, which blocked
the proliferation ofthe DN1 T cell line that normally occurs
when M. tuberculosis antigen is presented by CD1+ mono-
cytes (data not shown) . Coculture of DN1 with antigen-
pulsed C1R.CD1b cells induced anergy as indicated by a de-
creased proliferative response upon restimulation (Fig . 8) .
However, when 10 N,g/ml ofanti-CD1b mAb was included
during the preincubation phase of anergy induction, the
development ofDN1 T cell anergy was prevented (Fig. 8) .
IL-2 Did Not Prevent the Induction ofAnergy .
￿
Considerable
interest has been generated by the question of whether
IL-2 can prevent the induction of T cell anergy . At least
one report (58) demonstrated that the addition of IL-2 to
cultured T cells under conditions that would otherwise
lead to the induction of anergy can prevent the develop-
ment of human T cell hyporesponsiveness . However, this
area remains controversial since, in other systems, the pres-
ence of IL-2 did not appear to prevent the induction ofan-
ergy (59) . To clarify this point for the CD28- T cells we
Figure 9 .
￿
IL-2 did not prevent the induction of anergy. Anergy was in-
duced as described in the legend of Fig. 3 . 2 nM IL-2 was added during
the preincubation where indicated . Restimulation conditions : MTb 10
ng/ml (solid bars) ; no antigen (open bars) ; 2 nM IL-2 (hatched bars) .
2014
￿
Costimulation ofCD28- T Cells
have studied, experiments were performed to assess the ef-
fect ofIL-2 on the induction of anergy in DN1 T cells . We
also examined the effect of IL-1, because it has been shown
that a membrane form of IL-1 can be an important costim-
ulatory molecule for the activation ofT cells by monocytes
(60) . We found that the inclusion of IL-2 (Fig. 9) or IL-1
(data not shown) during the induction phase of anergy for
both CD28- T cell lines was unable to provide costimula-
tion and did not prevent the development of anergy .
Discussion
Work in several systems has shown that the binding of
CD80 or CD86 to CD28 is sufficient to provide a costim-
ulatory signal that leads to full T cell activation and preven-
tion ofT cell anergy . However, many human T cells are
CD28- , and the costimulatory requirements of these T
cells are presently not known . In this study, we have exam-
ined two representative CD28 - TCR-ot/R+ T cell lines .
DN1 and DN6 T cell lines killed antigen-pulsed CDI-
transfected ClR B-LCL but failed to proliferate in re-
sponse to these same APC . Furthermore, after recognition
of antigen presented by B-LCL transfectants, these T cells
were found to be anergic when assayed for subsequent pro-
liferation . The ability of the CD28- T cells to perform ef-
fector functions such as killing did not appear to depend on
costimulation . Such a phenomenon has been observed for
Thl and CD8+ cells and has been termed split or partial
anergy (61, 62) .
These data suggest that the CD28- T cells required a co-
stimulatory signal not expressed on the B-LCL, although
these cells do express the known costimulatory ligands
CD80 and CD86 and were able to provide costimulation
to human CD28 + T cell clones . The costimulatory ligand
required by CD28- TCR-ot/R+ T cells was present on
CD1 + monocytes, since this APC induced a brisk prolifer-
ative response without inducing anergy . The costimulatory
signal required by CD28- TCR-ot/R+ T cells was func-
tionally similar to B7-CD28, since antigen-specific activa-
tion ofDN1 and DN6 in the absence of the costimulatory
signal resulted in pronounced T cell anergy . Several lines of
evidence lead to the conclusion that the costimulatory sig-
nal required by DN1 and DN6 must be distinct from that
generated by the CD28-B7 axis . First, DN1 and DN6 did
not express CD28 . Second, the costimulatory ligand required
by DN1 and DN6 was unlikely to be CD80 or CD86 since
both were normally expressed on ClR cells, which in-
duced anergy and not proliferation or IL-2 production
upon antigen presentation to these T cells . Thus, the CD80
or CD86 molecules expressed by the CD1-transfected
C1R B-LCLs were not sufficient to prevent the induction
of anergy when DN1 or DN6 was cocultured with these
APC . In contrast, it has been previously shown that CD80
is sufficient to prevent the development ofT cell anergy in
human CD4+ T cell clones dependent on the CD28-B7
pathway (11), and our own studies showed that the
CD80+86+ ClR B-LCLs were able to fully activate
CD28+ T cell clones without inducing anergy . Lastly,CTLA4-Ig, which binds with high avidity to CD80 and
CD86 and competitively inhibits costimulation by this
pathway, could not inhibit DN1 T cell proliferation that
occurred when antigen was presented by the CD 1 + mono-
cytes. Together, these data indicate that a distinct costimu-
latory pathway exists and is critical for the proliferation of
CD28- T cells such as DN1 and DN6.
Experimentally, T cell anergy has been induced by chem-
ically modifying the APC using paraformaldehyde or the
cross-linking agent, 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (10). Alternatively, investigators have used artifi-
cial APC such as COS or Chinese hamster ovary cells
transfected with CD80 or CD86 to provide a costimulatory
signal (3) . These systems have been useful for dissecting the
function of the CD80 and CD86 costimulatory ligands, but
their in vivo relevance is limited. The APC used in the ex-
periments described here are closely analogous to a major
population ofAPC in vivo (i.e., B lymphoblasts, activated
monocytes, and tissue macrophages), and neither the sur-
face of the lymphoblastoid cell lines nor the CD1 + mono-
cytes were chemically modified. Thus, anergy was induced
by live APC. In addition, the system described here pro-
vides an example of a costimulatory molecule that is ex-
pressed on cells of the myeloid lineage but not on cells of
the B cell lineage. Johnson and Jenkins reported that freshly
isolated monocytes and the U937 human monocytic leuke-
mia cell line can provide a costimulatory signal to T cells
that is independent of the CD28-B7 axis (63). Freshly iso-
lated monocytes and myeloid tumor cell lines lack expres-
sion of CD1, which is required for antigen recognition by
the DN1 and DN6 T cell lines, and, consequently, we have
been unable to ascertain whether the costimulatory signal
provided by these APC is similar in function to the ligand
expressed by the CD1+ monocytes. Nevertheless, these ex-
periments highlight important differences between types of
APC. Specialized APC such as macrophages, dendritic cells,
and Langerhans cells express a full array of antigen-present-
ing molecules, adhesion molecules, and costimulatory mol-
ecules. The expression of CM and novel costimulatory mol-
ecules by the GM-CSF/IL-4-treated monocytes is critical
for the activation and expansion of certain T cell subsets
such as CD4-8- TCR-cx/R+ T cells, as exemplified by the
CD28- DN1 and DN6 T cell lines.
The role of the B7-CD28 axis in peripheral tolerance
and T cell activation and its therapeutic potential for treat-
ing cancer, transplant rejection, and autoimmune disease
are rapidly advancing areas ofinvestigation. However, most
in vivo studies have been carried out in mice, and there ex-
ist important differences between human and murine T cell
costimulation. Whereas most murine T cells express CD28
(64), many human T cells do not. These CD28 - T cells in-
clude approximately half of the circulating CD8+ and
CD4-8- T cells (38, 39, 51, 65) . All of these T cell subsets
have been proposed to be important in human cancer im-
munity (66-69), graft rejection, and autoimmunity-situa-
tions in which manipulation of the CD28-B7 axis has been
associated with beneficial effects in the murine system.
Clonal expansions of CD28- CD8+ T cells have been re-
ported in the peripheral blood of normal individuals (70)
and patients with autoimmune diseases (71, and Behar, S. M.,
unpublished observations) . The numbers of CD28-CD8+
T cells and CD28-CD4+ T cells are increased in the pe-
ripheral blood and lung of HIV' patients (72) . Among hu-
man CD4+ T cells, there are CD28-high and -low expres-
sors, and 1-5% of the peripheral blood CD4+ T cells are
CD28- ; these seem to form a distinct subset of T cells that
have a limited TCR repertoire and poor proliferative capac-
ity to alloantigen (73, 74) . Although CD28- and CD28+ T
cells have similar cloning efficiency (65), the difficulty es-
tablishing long-term CD28- T cell lines and clones may
reflect a requirement for a costimulatory signal other than
CD28, which may be provided only by specialized APC
such as the CD 1+ monocytes we have used in this study.
Furthermore, evidence from studies in the mouse also sug-
gests the existence of costimulatory molecules other than
CD28. Several groups have demonstrated that the genera-
tion ofprimary T cell responses is not impaired in CTLA41g-
transgenic mice or in mice made deficient in CD28 by
targeted gene disruption (75, 76), both of which have ab-
normal T cell dependent antibody production presumably
as a result of deficient CD28-B7 signaling. Thus, a role for
C1328-independent T cells in both normal immunity and
in a variety of disease states is strongly indicated, and a bet-
ter understanding of CD28-independent costimulatory
pathways is essential. The abundance of human CD28- T
cells together with the functional data presented in this re-
port suggest the existence of alternate costimulatory path-
ways independent of the B7-CD28 axis, which may be of
general importance to CD28- T cells.
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